سرطان الخلايا الكبدية (BCLC Stage B): ماذا تفعل عندما لا يحقق TACE أو TARE استجابة موضوعية

References

DOI: 10.1097/HEP.0000000000000466

Patients with BCLC Stage B HCC should be treated with transarterial chemoembolization (Level 1, Strong Recommendation).

AASLD advises systemic therapy in patients with intermediate HCC who are unsuitable for or refractory to locoregional therapies due to contraindications, worsening hepatic dysfunction, progression of HCC, or lack of objective response (Level 3, Strong Recommendation).

Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis should be offered atezolizumab plus bevacizumab or durvalumab plus tremelimumab as preferred first-line therapy options (Level 2, Strong Recommendation).